Rohto Pharmaceutical approved the year-end dividend plan at the Board of Directors meeting held on May 21, 2026, and implemented a conversion price adjustment applicable from April 1, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4527","jir_company_name":"Rohto Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-05-21","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4527-20260521-02.pdf","jir_short_summary":"Rohto Pharmaceutical approved the year-end dividend plan at the Board of Directors meeting held on May 21, 2026, and implemented a conversion price adjustment applicable from April 1, 2026.","jir_summary":"### Overview of Capital Policy\nRohto Pharmaceutical approved a dividend of 25 yen per share for the fiscal year ending March 2026 at the Board of Directors meeting on May 21, 2026. As a result, the conversion price of the convertible bond-type convertible bonds with European yen denomination maturing in 2026, applicable from April 1, 2026, was adjusted. The conversion price before adjustment was 2,828.5 yen, but after adjustment, it became 2,817.2 yen. The reason for the adjustment is due to the dividend decision, following the provisions of the conversion price adjustment clause.\n\n### Impact on Shareholders and Future Outlook\nThe conversion price adjustment this time has changed the conversion conditions for existing convertible bonds into shares. The increase in dividends is considered part of shareholder returns, and future trends in dividend policies and capital policies are worth monitoring. The slightly lower post-adjustment conversion price may impact dilution risks and financial flexibility for fundraising.","jir_financial_highlights":"Pre-adjustment Conversion Price: 2,828.5 yen (Unknown)\nPost-adjustment Conversion Price: 2,817.2 yen (Unknown)\nYear-end Dividend: 25 yen (Unknown)","jir_category":"","jir_hashtags":"#RohtoPharmaceutical, #CapitalPolicy, #JapaneseStocks","jir_key_figures":"Pre-adjustment Conversion Price: 2,828.5 yen\nPost-adjustment Conversion Price: 2,817.2 yen\nYear-end Dividend: 25 yen","jir_meta_title":"\u3010Rohto Pharmaceutical\u3011Conversion Price Adjustment for April 2026 | May 21, 2026","jir_meta_description":"Rohto Pharmaceutical approved a year-end dividend plan and implemented a conversion price adjustment on May 21, 2026. Details of the capital policy and its impact on shareholders are explained.","jir_og_title":"\u3010Rohto Pharmaceutical\u3011Conversion Price Adjustment for April 2026 | May 21, 2026","jir_og_description":"Rohto Pharmaceutical decided on dividends and conversion price adjustments on May 21, 2026. Key points on shareholder returns and capital policy are explained.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7770,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-53621","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n